Gilead Sciences GILD
NASDAQ GILD
$151.80 +1.69 (+1.13%)
As of: Sep 21, 2026 · 10:57 AM EDT

Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023)

Gilead Sciences' (GILD) quarterly Income from Non-Controlling Interests came in at -$12.0 million in Q4 2023, down 71.43% on a YoY basis from -$42.0 million in Q4 2022, and down 50.0% quarter-over-quarter from -$8.0 million in Q3 2023.

Analysis

Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023) Analysis & Trends

Gilead Sciences (GILD) has reported Income from Non-Controlling Interests for 15 consecutive years, with -$12.0 million the latest figure, recorded in Q4 2023.

  • For the quarter ending Q4 2023, Income from Non-Controlling Interests fell 71.43% year-over-year to -$12.0 million; the trailing twelve-month figure through Sep 2024 stood at -$12.0 million (up 74.47% YoY), and the FY2023 full-year result was -$52.0 million, down 100.0% from the prior year.
  • Income from Non-Controlling Interests slipped to -$12.0 million in Q4 2023 per GILD's latest filing, from -$8.0 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at -$3.0 million in Q3 2019 and bottomed at -$26.0 million in Q1 2023.
  • Historically, Income from Non-Controlling Interests has averaged -$7.9 million across 5 years, with a median of -$7.0 million in 2019.
  • The sharpest annual moves came in 2019 and 2022: Income from Non-Controlling Interests sank 800.0% in 2019, then surged 50.0% in 2022.
  • Over 5 years, Income from Non-Controlling Interests stood at -$7.0 million in 2019, then changed by 0.0% to -$7.0 million in 2020, then gained by 14.29% to -$6.0 million in 2021, then decreased by 16.67% to -$7.0 million in 2022, then tumbled by 71.43% to -$12.0 million in 2023.
  • According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$12.0 million, -$8.0 million, and -$6.0 million for Q4 2023, Q3 2023, and Q2 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Amgen 208.48 Bn 194.49 Bn 7.24 Bn -
2 Gilead Sciences 186.29 Bn 183.02 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 128.79 Bn 120.93 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 80.66 Bn 72.67 Bn 3.93 Bn -
5 Moderna 61.46 Bn 56.32 Bn 52.00 Mn -
6 Argenx Se 61.28 Bn 56.10 Bn 1.37 Bn -
7 Alnylam Pharmaceuticals 32.04 Bn 28.73 Bn 992.69 Mn -
8 Biogen 31.84 Bn 30.56 Bn 1.96 Bn -
9 Roivant Sciences 28.74 Bn 29.43 Bn 1.16 Mn -100.77 Mn
10 Insmed 26.19 Bn 25.03 Bn 358.27 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -12.00 Mn
Sep 30, 2023 -8.00 Mn
Jun 30, 2023 -6.00 Mn
Mar 31, 2023 -26.00 Mn
Dec 31, 2022 -7.00 Mn
Sep 30, 2022 -3.00 Mn
Jun 30, 2022 -9.00 Mn
Mar 31, 2022 -7.00 Mn
Dec 31, 2021 -6.00 Mn
Sep 30, 2021 -6.00 Mn
Jun 30, 2021 -5.00 Mn
Mar 31, 2021 -7.00 Mn
Dec 31, 2020 -7.00 Mn
Sep 30, 2020 -7.00 Mn
Jun 30, 2020 -7.00 Mn
Mar 31, 2020 -13.00 Mn
Dec 31, 2019 -7.00 Mn
Sep 30, 2019 -3.00 Mn
Jun 30, 2019 -5.00 Mn
Mar 31, 2019 -7.00 Mn